AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 243.87

Change

+0.47 (+0.19)%

Market Cap

USD 130.02B

Volume

2.41M

Avg Analyst Target

USD 235.94 (-3.25%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Amgen Inc (AMGN) Stock Analysis:
Based on the Amgen Inc stock forecasts from 10 analysts, the average analyst target price for Amgen Inc is USD 235.94 over the next 12 months. Amgen Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Amgen Inc is Slightly Bearish, which is based on 4 positive signals and 9 negative signals. At the last closing, Amgen Inc’s stock price was USD 243.87. Amgen Inc’s stock price has changed by +1.94% over the past week, -4.00% over the past month and -2.99% over the last year.

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheu ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

+1.35 (+2.14%)

USD194.16B 1,689.87 30.79
SNY Sanofi

+0.53 (+1.02%)

USD127.91B 18.35 13.82
GILD Gilead Sciences Inc

-0.13 (-0.21%)

USD78.23B 17.42 11.09
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

-0.73 (-0.37%)

USD29.16B 19.15 11.65
HZNP Horizon Therapeutics Public Li..

+0.39 (+0.43%)

USD20.79B 39.84 16.54
GRFS Grifols S.A

+0.18 (+1.39%)

USD11.99B 88.79 20.08
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
CRXT Clarus Therapeutics Holdings I..

+0.08 (+17.34%)

USD0.02B N/A N/A
CRXTW Clarus Therapeutics Holdings I..

+0.01 (+7.94%)

N/A N/A N/A

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
UBIO ProShares UltraPro Nasdaq.. 6.41 % 0.95 %

N/A

USD0.02B
UEFY:XETRA UBS ETF SICAV - SBI Forei.. 1.09 % 0.20 %

-0.02 (-0.20%)

USD0.22B
EKUS:PA BNP Paribas Easy - MSCI U.. 0.00 % 0.18 %

-0.11 (-0.65%)

USD1.05B
3SUR:F iShares IV Public Limited.. 0.00 % 0.23 %

+12.80 (+0.87%)

N/A
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

+0.07 (+0.16%)

USD0.07B
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.13 %

+0.14 (+0.87%)

N/A
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.51 %

-1.60 (-0.52%)

USD0.25B
MJMT:F Amundi Index Solutions - .. 0.00 % 0.13 %

-0.05 (-0.06%)

USD0.32B
SXRU:F iShares VII Public Limite.. 0.00 % 0.33 %

-0.50 (-0.14%)

USD0.80B
UIMP:F UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

-0.88 (-0.57%)

USD1.94B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.05 (+1.06%)

USD0.46B
BBCK:XETRA Invesco Markets III plc -.. 0.00 % 0.39 %

-0.22 (-0.53%)

USD0.07B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.51 %

-1.20 (-0.39%)

USD0.25B
SXRU:XETRA iShares VII Public Limite.. 0.00 % 0.33 %

-1.35 (-0.38%)

USD0.80B
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-0.28 (-0.20%)

USD0.44B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
UET1:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

-0.26 (-1.27%)

USD0.15B
UIMP:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

-1.66 (-1.07%)

USD1.94B
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
ZPAY:CA BMO Premium Yield ETF 0.00 % 0.65 %

-0.25 (-0.88%)

N/A
ESNG Direxion MSCI USA ESG - L.. 0.00 % 0.40 %

N/A

N/A
TACE Trend Aggregation Conserv.. 0.00 % 1.87 %

N/A

N/A
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
FLXX:LSE Franklin LibertyShares IC.. 0.00 % 0.45 %

-0.07 (-0.26%)

N/A
FRGD:LSE Franklin LibertyQ Global .. 0.00 % 0.45 %

-0.01 (-0.03%)

N/A
FRGE:LSE Franklin LibertyQ Global .. 0.00 % 0.25 %

-0.08 (-0.24%)

N/A
ZPAY-F:CA BMO Premium Yield ETF 0.00 % 0.65 %

-0.04 (-0.14%)

N/A
ZPAY-U:CA BMO Premium Yield ETF 0.00 % 0.65 %

-0.01 (-0.03%)

N/A
BUYB:PA Invesco Markets III plc -.. 0.00 % 0.39 %

-0.13 (-0.31%)

USD0.07B
SBUY:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

-19.00 (-0.54%)

USD0.07B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.70 (+1.55%)

USD0.10B
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.06 %

+0.26 (+0.34%)

USD34.16B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.35 (-1.14%)

USD8.57M
BLV Vanguard Long-Term Bond I.. 0.00 % 0.05 %

+0.04 (+0.05%)

USD8.77B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

+0.21 (+0.34%)

USD0.41B
DIA SPDR Dow Jones Industrial.. 0.00 % 0.16 %

+0.55 (+0.17%)

USD28.42B
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

+0.31 (+0.69%)

USD0.20B
FLQD Franklin LibertyQ Global .. 0.00 % 0.45 %

+0.12 (+0.36%)

USD0.03B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

+0.15 (+0.13%)

USD7.49B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.59 %

+0.20 (+0.36%)

USD0.21B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.58 %

+0.81 (+1.11%)

USD0.32B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.21 (-1.48%)

USD1.80M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.21 (-1.48%)

USD1.80M
UDOW ProShares Trust - ProShar.. 0.00 % 0.95 %

+0.25 (+0.44%)

USD0.72B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.18 %

+1.75 (+0.22%)

USD1.69B
VVO:CA Vanguard Global Minimum V.. 0.00 % 0.36 %

+0.08 (+0.25%)

USD0.04B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.26 %

+0.01 (+0.02%)

USD0.30B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.65 %

+0.08 (+0.33%)

USD0.20B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

+0.12 (+1.02%)

USD0.06B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.35 (+0.43%)

USD0.44B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

+0.07 (+0.57%)

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.07 (+1.31%)

USD0.46B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

+0.04 (+0.93%)

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.06 (+1.14%)

USD0.45B
CIND:LSE iShares VII Public Limite.. 0.00 % 0.33 %

-1.84 (-0.49%)

USD0.80B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

+0.09 (+0.50%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.40% 67% D+ 88% B+
Dividend Return 1.72% 67% D+ 70% C-
Total Return 10.13% 67% D+ 89% B+
Trailing 12 Months  
Capital Gain -3.37% 11% F 68% D+
Dividend Return 2.93% 33% F 52% F
Total Return -0.44% 11% F 69% D+
Trailing 5 Years  
Capital Gain 55.27% 67% D+ 75% C
Dividend Return 19.55% 67% D+ 71% C-
Total Return 74.82% 67% D+ 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 7.62% 71% C- 59% F
Dividend Return 2.98% 60% D- 73% C
Total Return 10.60% 71% C- 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 13.41% 57% F 79% C+
Risk Adjusted Return 79.04% 71% C- 92% A-
Market Capitalization 130.02B 22% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.05 33% F 28% F
Price/Book Ratio 142.72 11% F 1% F
Price / Cash Flow Ratio 14.04 44% F 29% F
EV/EBITDA 14.48 33% F 33% F
Management Effectiveness  
Return on Equity 111.67% 100% A+ 98% A+
Return on Invested Capital 16.58% 44% F 83% B
Return on Assets 9.91% 67% D+ 90% A-
Debt to Equity Ratio 495.85% 11% F 6% F
Technical Ratios  
Dividend Yield 3.19% 56% F 26% F
Short Ratio 6.83 11% F 10% F
Short Percent 3.73% 11% F 49% F
Beta 0.59 44% F 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector